Lirilumab Antibody is a research-grade biosimilar monoclonal antibody targeting CD158. It is a human IgG4-kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity by SDS-PAGE. For research use only.
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
Product Name:
Lirilumab Antibody
SKU:
GXBS00200
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
CD158 antigen-like family member A
Isotype:
IgG4-kappa
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
BMS-986015, IPH2102, 1000676-41-4
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
